Earnings Flash ONCOCYTE CORPORATION Posts Q1 Revenue 297,000, vs. Street Est of 340,000 - Marketscreener.com
| ABNX Stock | EUR 1.20 0.01 0.83% |
About 62% of Abionyx Pharma's investor base is looking to short. The analysis of current outlook of investing in Abionyx Pharma SA suggests that many traders are alarmed regarding Abionyx Pharma's prospects. The current market sentiment, together with Abionyx Pharma's historical and current headlines, can help investors time the market. In addition, many technical investors use Abionyx Pharma SA stock news signals to limit their universe of possible portfolio assets.
Abionyx |
Earnings Flash ONCOCYTE CORPORATION Posts Q1 Revenue 297,000, vs. Street Est of 340,000 Marketscreener.com
Read at news.google.com
 |
Abionyx Pharma Fundamental Analysis
We analyze Abionyx Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Abionyx Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Abionyx Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Asset
Net Asset Comparative Analysis
Abionyx Pharma is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Abionyx Pharma SA Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Abionyx Pharma stock to make a market-neutral strategy. Peer analysis of Abionyx Pharma could also be used in its relative valuation, which is a method of valuing Abionyx Pharma by comparing valuation metrics with similar companies.
Peers
Abionyx Pharma Related Equities
| AB | AB Science | 38.46 | ||||
| NANO | Nanobiotix | 3.32 | ||||
| GNFT | Genfit | 0.84 | ||||
| IPH | Innate Pharma | 2.09 |
Complementary Tools for Abionyx Stock analysis
When running Abionyx Pharma's price analysis, check to measure Abionyx Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abionyx Pharma is operating at the current time. Most of Abionyx Pharma's value examination focuses on studying past and present price action to predict the probability of Abionyx Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abionyx Pharma's price. Additionally, you may evaluate how the addition of Abionyx Pharma to your portfolios can decrease your overall portfolio volatility.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |